TCHP(多西他赛+卡铂+曲妥珠单抗+帕妥珠单抗)方案在Her-2阳性乳腺癌新辅助治疗中的临床治疗价值

Clinical Value of TCHP(Docetaxel+Carboplatin+Trastuzumab+Per⁃tuzumab)Regimen in the Neoadjuvant Treatment of Her-2 Positive Breast Cancer

目的评价Her-2阳性乳腺癌新辅助治疗中应用TCHP(多西他赛+卡铂+曲妥珠单抗+帕妥珠单抗)方案的效果。方法方便选择该院乳腺外科在2019年6月—2021年8月期间就诊的80例Her-2阳性乳腺癌患者,根据随机数表法进行分组,对照组与研究组各为40例。对照组给予曲妥珠单抗联合化疗,研究组给予TCHP(多西他赛+卡铂+曲妥珠单抗+帕妥珠单抗)方案治疗,对比两组Her-2阳性乳腺癌患者的治疗有效率、癌胚抗原(CEA)、血清糖类抗原125(CA125)、血清糖类抗原153(CA153)水平。结果研究组治疗总有效率87.50%高于对照组62.50%,差异有统计学意义(χ^(2)=6.666,P=0.009)。研究组PCR(65.00%)高于对照组(40.00%),差异有统计学意义(χ^(2)=5.012,P=0.025)。研究组治疗后的CEA(13.79±3.52)ng/mL、CA125(20.15±1.52)U/mL、CA153(18.65±7.65)U/mL水平均小于对照组(20.15±2.98)ng/mL、(32.63±2.69)U/mL、(27.56±8.85)U/mL,差异有统计学意义(t=8.721、25.545、4.817,P<0.05)。结论Her-2阳性乳腺癌新辅助治疗中应用TCHP(多西他赛+卡铂+曲妥珠单抗+帕妥珠单抗)方案可以取得理想效果。

Objective To evaluate the effect of TCHP(docetaxel+carboplatin+trastuzumab+pertuzumab)regimen in the neoadjuvant treatment of Her-2 positive breast cancer.Methods A total of 80 patients with Her-2-positive breast cancer who were treated by the Department of Breast Surgery in the hospital from June 2019 to August 2021 were conveniently selected.According to the random number table method,the control group and the research group were divided into 40 cases.The control group was given trastuzumab combined with chemotherapy,and the study group was given TCHP(docetaxel+carboplatin+trastuzumab+pertuzumab)regimen.The treatment efficiency,car‐cinoembryonic antigen(CEA),serum carbohydrate antigen 125(CA125),serum carbohydrate antigen 153(CA153)levels of the two groups of Her-2 positive breast cancer patients were compared.Results The total effective rate of the study group was 87.50%higher than that of the control group 62.50%,and the difference was statistically signifi‐cant(χ^(2)=6.666,P=0.009).The PCR in the study group(65.00%)was higher than that in the control group(40.00%),and the difference was statistically significant(χ^(2)=5.012,P=0.025).CEA(13.79±3.52)ng/mL,CA125(20.15±1.52)U/mL,CA153(18.65±7.65)U/mL in the study group after treatment were lower than those of the control group(20.15±2.98)ng/mL,(32.63±2.69)U/mL,(27.56±8.85)U/mL,and the difference was statistically significant(t=8.721,25.545,4.817,P<0.05).Conclusion The application of TCHP(docetaxel+carboplatin+trastuzumab+pertu‐zumab)regimen in the neoadjuvant treatment of Her-2 positive breast cancer can achieve ideal results.